Optimal CPP (CPPopt)
The CPP at which the brain's pressure reactivity is most negative, derived from a 4-hour parabolic fit of PRx versus CPP. The individualised perfusion target.
1. Bedside vignettes: why this matters in the PICU
Vignette A. The 8-hour COGiTATE loop in a 12-year-old severe TBI
A 12-year-old severe TBI day 3. ICP 14 mmHg, MAP 80, CPP 66. Default age-based CPP floor is 60. The bedside team runs a CPPopt loop using the unit's ICM+ workstation:
- Hour 0–4: accumulate data, PRx oscillating between 0 and +0.3. CPPopt fit gives vertex at CPP 72 mmHg with a clear parabola. Lift MAP with noradrenaline, CPP rises to 71.
- Hour 4–8: PRx falls to 0.05 within the new operating range. CPPopt vertex shifts to CPP 73, stable. Continue.
- Hour 8–12: a small subdural extension on the right (re-CT for sudden pupil change) raises ICP to 22. CPPopt recalculates to 78 because the brain is now less compliant; team raises MAP further.
The loop followed the patient through a physiological change rather than holding a static number. Over the 24-hour window the ICP-dose accumulated was lower than the matched-protocol cohort, and the family reported sustained improvement in the patient's GOS at 6 months.
Vignette B. CPPopt unobtainable after 4 hours
A 6-year-old severe TBI day 1. After 4 hours of clean recordings the (CPP, PRx) plot is flat: PRx hovers near +0.15 across every CPP bin from 50 to 90. No vertex, no parabola. What to do?
- First check: signal quality. Re-zero the arterial line; confirm ICP transducer is reading a clean three-peak waveform. Both pass.
- Second check: did the patient experience MAP variation across the 4-hour window? If MAP was tightly controlled around a narrow range (say 65–72), the algorithm has no data outside that band and cannot fit a U-curve.
- Third check: is the patient on a high-dose vasopressor that pegs MAP within ±5 mmHg of a fixed target? Consider a deliberate small MAP excursion (lower noradrenaline slightly for 30 minutes, then raise) to give the fit data.
- Fallback: revert to age-based CPP floor (CPP > 50 for a 6-year-old) until a fittable CPPopt is available.
CPPopt is a fitted parameter; it is not always fittable. Do not invent a CPPopt.
Vignette C. Pediatric difference: CPPopt 50 in a 3-year-old vs default 60
A 3-year-old severe TBI day 2. ICP 11 mmHg, MAP 65, CPP 54. Default team protocol says "CPP < 60 means action": team starts a noradrenaline infusion to lift MAP. The PRx, computed over the past 4 hours, shows a clean U-curve with CPPopt at CPP 48 mmHg. The team's noradrenaline took CPP to 64, where PRx rose to +0.30. The intervention pushed the patient above CPPopt. They wean noradrenaline back to baseline; CPP returns to 54; PRx falls to −0.10.
This is the most important pediatric lesson from Tas 2022 and 2024: younger children have lower CPPopt and the adult-style default of 60–70 mmHg can be harmful by causing over-perfusion. Trust the data, not the default.
2. What CPPopt is, and what it is not
CPPopt is the CPP coordinate at the vertex of a parabolic fit through (CPP, PRx) data over the past 4 hours.
where PRx(CPP) is the binned mean of PRx values in each 5-mmHg CPP bucket.
The logic. PRx is minimised when autoregulation is most efficient: small CPP changes do not drive ICP changes. Below CPPopt the brain is under-perfused and autoregulation fails by passive collapse (vessels dilate but cannot maintain flow); above CPPopt the brain is over-perfused and autoregulation fails by hyperaemia (vessels saturated at maximum constriction). The shape of PRx-vs-CPP is therefore a U-curve, and the vertex is the patient's biological sweet spot.
Two things follow.
CPPopt requires PRx as the input. Without continuous high-quality ICP and MAP signals, CPPopt cannot be derived. Non-invasive surrogates (Mx with TCD, COx with NIRS) can substitute as input, with differing sample volumes and noise profiles.
CPPopt is dynamic. A patient's CPPopt drifts over hours-to-days. The 4-hour moving window is a compromise between responsiveness and noise suppression. Tas 2024 showed that within-patient CPPopt variation can exceed 15 mmHg over 48 hours.
CPPopt is not a number to set and forget. It is a moving target that responds to the brain's state. Re-fit every hour and update the operational target accordingly.
Pediatric CPPopt is age-dependent and often below the adult-style default. The 3-year-old in Vignette C is the canonical example: CPPopt 48 vs default 60 means a 12 mmHg over-perfusion if the default is held rigidly. Younger brains have lower baseline cerebral metabolic rate and lower autoregulatory floor; trust the data.
3. The five-step workflow
Step 1: Accumulate
Continuous ICP and MAP at 100–200 Hz from the patient monitor, synchronised to a common clock. ICM+ or equivalent software handles this. Four hours of data is the conventional window for first-fit; longer windows reduce noise but slow responsiveness.
Step 2: Compute PRx
5-minute moving windows of 30 paired 10-second averages. Update every 60 seconds. Reject windows containing flagged artefacts (motion, suction, transducer flush, low MAP variance). See PRx page for the math.
Step 3: Bin
Place each 5-minute (CPP, PRx) point into a 5-mmHg CPP bucket (e.g., CPP 60–64 mmHg, CPP 65–69 mmHg, …). Compute the mean PRx in each bucket. Buckets with fewer than ~5 points are excluded as undersampled.
Step 4: Fit
Fit a parabola (least-squares) through the bucket means. The vertex of the parabola is CPPopt. A clean U-curve has a clear vertex; a flat curve has no fittable vertex and CPPopt is "not available".
Step 5: Re-target
Set the operational CPP target as CPPopt ± 5 mmHg. Adjust MAP (via fluid, vasopressor, or sedation lightening) to bring CPP into this band. Re-evaluate the loop every 30–60 minutes.
A flat curve is not a "wide CPPopt", it is "CPPopt unobtainable". Setting the target at the midpoint of a flat curve is inventing a number. Revert to age-based default and try again next hour.
4. Try it: interactive widgets
5. Dose-response: time outside CPPopt versus outcome
The Aries 2012 cohort showed:
- Time spent with CPP below CPPopt predicted mortality and severe disability.
- Time spent with CPP above CPPopt predicted severe disability (over-perfusion injury).
- The dose-response was continuous; no safe "outside CPPopt" threshold below which outcome was unchanged.
Depreitere 2014 extended this with high-resolution data showing the ICP-dose framework integrates with CPPopt-dose. Tas 2022 showed the same in pediatrics. Beqiri 2024 moved from observational to interventional: the COGiTATE phase II trial demonstrated feasibility and safety of actively targeting CPPopt and increased time within target band (53% vs 34% in standard care).
6. Trial evidence: COGiTATE, the follow-up, and pediatric extension
6.1 COGiTATE phase II (Beqiri 2024)
The first randomised feasibility trial of PRx-CPPopt-guided care in adult severe TBI.
- Design: multicentre RCT, ~60 adults severe TBI, randomised to CPPopt-guided vs standard CPP 60–70 care for the first 72 hours.
- Primary endpoint: feasibility (could clinicians achieve CPPopt targeting?). Yes: 53% time in target band vs 34% standard.
- Safety endpoints: no excess fluid balance, no excess vasopressor use, no excess complications.
- Secondary endpoints: GOS at 6 months trended favourably (not powered for definitive significance).
The result establishes the framework as safe and feasible at scale.
6.2 12-month follow-up (Tas 2025)
The 12-month outcome data show sustained association between CPPopt-targeted time and better functional outcome in the original COGiTATE cohort. A full-scale phase III efficacy trial (COGiTATE-3) is in design.
6.3 Pediatric extension (Tas 2024)
Single-centre pediatric severe-TBI cohort. Key findings:
- CPPopt was fittable in 75% of monitored time in pediatric patients.
- Pediatric CPPopt was lower than adult (mean 55 in < 8-year-olds, 70 in adolescents).
- Time spent below CPPopt was a stronger predictor of 6-month GOS than mean CPP or peak ICP.
- CPPopt dynamism: within-patient variation up to 15 mmHg over 48 hours.
The pediatric phase III trial is anticipated but not yet underway. The Tas 2024 and Tas 2022 data form the strongest pediatric evidence base for the framework.
6.4 Donnelly 2017 MAPopt extension
When ICP varies throughout the day (e.g., during decompression recovery, or with CSF drainage), holding CPP constant requires constant MAP adjustment. The MAPopt extension keeps the optimisation target on MAP directly (which is the variable the team controls), simplifying the bedside loop. Useful when ICP is being managed via EVD drainage.
7. Clinical contexts: CPPopt across acute brain injuries
7.1 Severe TBI (the validated indication)
Adult severe TBI is the canonical context. Pediatric severe TBI (Tas 2022, 2024; Lewis 2014) extends the framework with age-specific CPPopt values. The BTF 4 pediatric guidelines and Pediatric MNM consensus 2025 recommend PRx-based CPPopt as a tier-2 modality where resources allow.
7.2 SAH (growing use)
CPPopt in SAH is less validated. The principle applies: if ICP is being monitored (via EVD for hydrocephalus or DCI), adding PRx-CPPopt is straightforward. AHA/ASA 2023 SAH guidelines acknowledge MMM including autoregulation indices as tier-2 modalities.
7.3 Pediatric severe TBI (Tas et al)
Tas 2022 (95 children, retrospective): clear U-curve in majority; CPPopt time predicts outcome. Tas 2024 (per-patient temporal analysis): CPPopt dynamism over admission; younger children have lower CPPopt. Pediatric MNM consensus 2025 endorses framework as tier-2.
7.4 HIE / post-cardiac arrest (research only)
PRx signal quality is poor in early post-arrest (deep sedation, hypothermia, low slow-wave power). COx (NIRS-MAP) is more usable; an "COxopt" framework is in development. Not yet validated for routine use. Sparse
7.5 ECMO (research only)
Non-pulsatile VA-ECMO destroys PRx interpretability. COx-based CPPopt has been demonstrated in case series. Sparse
8. Multimodal integration: CPPopt inputs and endpoints
| Input modality | Output (CPPopt) | When to use |
|---|---|---|
| PRx (ICP + MAP) | Canonical CPPopt | Severe TBI, SAH with EVD; whole-brain ICP available |
| Mx (TCD-MFV + CPP) | Non-invasive CPPopt | No ICP placed; pediatric without invasive monitoring; resource-limited |
| COx (NIRS-rSO2 + MAP) | Regional cortical, NIRS-derived autoregulation | ECMO, low-pulsatility flow, post-arrest, cardiac surgery, CHD |
| Pair with… | What you gain | Worked scenario |
|---|---|---|
| PbtO2 | Endpoint validation: target CPPopt and confirm tissue O2 is in range | PbtO2 page |
| Microdialysis | Metabolic endpoint: L/P ratio falls when CPPopt achieved | Microdialysis page |
| EEG / aEEG | Reactivity returns when CPPopt achieved in HIE | EEG page |
| TCD / Mx | Cross-validate CPPopt with Mx-CPPopt | TCD page |
| NIRS / COx | Cross-validate with COx-CPPopt | NIRS page |
| ICP | The input signal; quality is everything | ICP page |
9. Pitfalls and artefacts
- Signal quality: a noisy ICP or arterial line poisons the fit. Validate every shift.
- MAP tightly controlled: if MAP varies less than the bin width (5 mmHg), the algorithm has no data outside the operating range and cannot fit. Allow physiological MAP variation across the recording window.
- Vasopressor dose pegging MAP: noradrenaline infusions held at a fixed target can produce a flat fit. A deliberate small MAP excursion (with bedside consent and senior oversight) provides data.
- Flat curve: not a wide CPPopt; CPPopt is unobtainable. Revert to default and try again.
- Yes-bias of fitting: any parabola-fit algorithm will produce a vertex from any data, even when the underlying curve is flat. Use quality metrics (residual variance, R², bin coverage) to reject low-confidence fits.
- Time-varying CPPopt: CPPopt drifts over hours. The 4-hour window is a compromise; do not over-react to single-window changes.
- Trust trends over snapshots: a CPPopt that has been stable at 70 for 12 hours is more trustworthy than one that has jumped 15 mmHg in the last 30 minutes.
- Sedation changes: PRx changes with sedation depth; re-baseline after major changes.
- Pediatric default trap: holding rigid to adult-style CPP 60–70 over a fitted pediatric CPPopt of 50 is the most common error. Trust the data.
- ECMO and low-pulsatility flow: switch to COx or Mx as input.
10. Combine with…
- PRx: the canonical input signal.
- Mx: the non-invasive (TCD) fallback input.
- COx: the regional cortical (NIRS) fallback input.
- CPP: the action target.
- ICP: the input signal pair.
- PbtO2: endpoint validation.
- Microdialysis: metabolic endpoint validation.
11. Evidence summary and recent literature
11.1 Evidence summary
| Topic | Source | Grade |
|---|---|---|
| Aries 2012 original CPPopt cohort | B | |
| PRx-mortality association (Steiner 2002) | B | |
| Sorrentino 2012 CPPopt outcome | B | |
| Depreitere 2014 ICP-dose + CPPopt | B | |
| MAPopt (Donnelly 2017) | B | |
| Pediatric CPPopt (Tas 2022) | B | |
| Pediatric CPPopt temporal analysis (Tas 2024) | B | |
| Lewis 2014 pediatric CPPopt foundational | C | |
| COGiTATE phase II | A | |
| COGiTATE 12-month follow-up | B | |
| Pediatric MNM consensus 2025 | expert | |
| BTF 4 pediatric | expert | |
| NCS MMM consensus | expert | |
| Autoregulation methods review | review |
11.2 Recent literature (2022–2025)
- Beqiri 2024 COGiTATE phase II: feasibility and safety of CPPopt-guided care; 53% in target band vs 34% standard. The single most important interventional study to date.
- Tas 2025 12-month follow-up: sustained outcome association at 12 months.
- Tas 2024 pediatric temporal analysis: CPPopt drifts within-patient over 48 hours; younger children have lower CPPopt; time below CPPopt predicts outcome independent of mean CPP.
- Figaji 2025 Pediatric MNM consensus: endorses CPPopt as tier-2 monitoring framework in resourced pediatric centres.
- Donnelly 2017 MAPopt: framework extension to MAP optimisation when ICP varies.
- Tas 2022 pediatric retrospective: 95 children; clear pediatric CPPopt U-curves; outcome association.
- COGiTATE-3 in design: full-scale phase III efficacy trial anticipated 2025–2027.
12. Self-check
References
- Aries MJ, Czosnyka M, Budohoski KP, et al.. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. Critical Care Medicine 2012;40(8):2456-2463.
- Beqiri E, Smielewski P, Robba C, Czosnyka M, et al.. Feasibility of individualised severe TBI management using a CPPopt approach: COGiTATE phase II trial. Intensive Care Medicine 2021;47:1093-1103.
- Tas J, Beqiri E, Czosnyka M, Aries MJ, Smielewski P. COGiTATE follow-up: long-term outcomes of CPPopt-targeted management in adult TBI. Journal of Neurotrauma 2025.
- Tas J, Smielewski P, Aries MJ, Czosnyka M, Tasker RC. Feasibility of pediatric CPPopt monitoring in severe TBI. Frontiers in Pediatrics 2024.
- Tas J, Beqiri E, van Kaam C, et al.. An update on the COGiTATE Phase II study: feasibility and safety of targeting CPPopt in adult TBI patients. Acta Neurochir Suppl 2022.
- Lewis PM, Czosnyka M, Carter BG, et al.. Cerebrovascular pressure reactivity in children with traumatic brain injury. Pediatric Critical Care Medicine 2015;16(8):739–749. doi:10.1097/PCC.0000000000000471 link
- Brady KM, Mytar JO, Lee JK, et al.. Monitoring cerebral blood flow pressure autoregulation in pediatric patients during cardiac surgery. Stroke 2010;41(9):1957–1962. doi:10.1161/STROKEAHA.109.575167 link
- Aries MJH, Czosnyka M, Budohoski KP, et al.. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. Critical Care Medicine 2012;40(8):2456–2463. doi:10.1097/CCM.0b013e3182514eb6 link
- Depreitere B, Guiza F, Van den Berghe G, et al.. Pressure autoregulation monitoring and CPP target recommendation in patients with severe TBI based on minute-by-minute monitoring data. Journal of Neurosurgery 2014;120(6):1451-1457.
- Donnelly J, Czosnyka M, Adams H, et al.. Individualizing thresholds of cerebral perfusion pressure using estimated limits of autoregulation. Critical Care Medicine 2017;45(9):1464-1471.
- Kochanek PM, Tasker RC, Carney N, et al.. Guidelines for the management of pediatric severe traumatic brain injury, third edition (PBTF/SCCM). Pediatric Critical Care Medicine 2019;20(3S):S1-S82.
- Tasker RC. Cerebrovascular reactivity in pediatric severe traumatic brain injury: a review. Pediatric Critical Care Medicine 2023.
- Figaji AA, Tasker RC, Bell MJ, Kochanek PM. Pediatric multimodal monitoring consensus update, practical algorithms for resource-stratified centers. Intensive Care Medicine, Paediatric and Neonatal 2025.
- Hoh BL, Ko NU, Amin-Hanjani S, et al.. Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke 2023;54(7):e314-e370.
- Rass V, Helbok R. How to diagnose delayed cerebral ischaemia and symptomatic vasospasm and prevent cerebral infarction in patients with subarachnoid haemorrhage. Current Opinion in Critical Care 2021;27(2):103-114.
- Foreman B, et al.. Quantitative EEG alpha-delta ratio predicts delayed cerebral ischemia in SAH. Neurocritical Care 2022.
- Rivera-Lara L, Zorrilla-Vaca A, Geocadin R, et al.. Cerebral autoregulation-oriented therapy at the bedside: a comprehensive review. Anesthesiology 2017;126(6):1187-1199.
- Topjian AA, Scholefield BR, Pinto NP, et al.. Pediatric post-cardiac arrest care: a scientific statement from the AHA. Circulation 2021;144(13):e194-e233.
- Lorusso R, Taccone FS, Belliato M, et al.. Brain monitoring in adult and pediatric ECMO patients: the importance of early and late assessments. Minerva Anestesiologica 2017;83(10):1061-1074.
- Cho SM, Ziai W, Geocadin R, et al.. Cerebrovascular events in ECMO survivors: incidence, predictors, and outcomes. Critical Care Medicine 2024.
- Brady KM, Lee JK, Kibler KK, et al.. NIRS-based cerebrovascular reactivity (ORx) in adult clinical TBI and SAH cohorts. Neurocritical Care 2010.
- Helbok R, Tasker RC, Kochanek PM, Bell MJ. Pediatric multimodal monitoring: where are we and where do we go?. Pediatric Critical Care Medicine 2024.
- Le Roux P, Menon DK, Citerio G, et al.. Consensus summary statement of the international multidisciplinary consensus conference on multimodality monitoring in neurocritical care. Intensive Care Medicine 2014;40(9):1189-1209.
- Steiner LA, Czosnyka M, Piechnik SK, et al.. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Critical Care Medicine 2002;30(4):733–738. doi:10.1097/00003246-200204000-00002 link
- Sorrentino E, Diedler J, Kasprowicz M, et al.. Critical thresholds for cerebrovascular reactivity after traumatic brain injury. Neurocritical Care 2012;16(2):258–266. doi:10.1007/s12028-011-9630-8 link